A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Sponsor
Zhao Weili
Study ID
NCT05883709
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tafasitamab Injection — DRUG
    The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients

Study Details

To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.

Key Dates

Start date
Jul 1, 2023
Status verified
May 2023
Primary completion
Dec 30, 2023
Completion
Dec 30, 2024

Study Design

Enrollment
15 participants (estimated)

Arms

  • Arm: Cohort 1
    Tafa combination therapy group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitors, Tafa combined with Lenalidomide plus chemotherapy (including ADC)
  • Arm: Cohort 2
    Tafa combination therapy group followed by sequential CAR T or transplantation

Primary Outcome Measure

objective remission rate [ Time Frame: at the end of Cycle 2 (each cycle is 28 days) ]

Related Studies